Drugs that contain Bimatoprost
1. Drug name - DURYSTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8629185 | ALLERGAN INC | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
Jul, 2031
(8 years from now) | |
| CN104367580A | ALLERGAN INC | Form Ii Of 7 - (3, 5-Dihydroxy - -2-(3-Hydroxy - -5 - Phenyl - -1 - Alkenyl) - Cyclopentyl] - N-Ethyl - -5 - Enamide (Bimatoprost), Preparation Method And Use Method Thereof |
Aug, 2017
(5 years ago) | |
| CN102712584B | ALLERGAN INC | 7-[3,5-Dihydroxy-2- (3-Hydoroxy-5-Phenyl-Pent-1-Enyl)- Cyclopentyl]-N-Ethyl-Hept-5-Enamide (Bimatoprost) In Crystalline Form Ii, Methdo For Preparation, And Method For Use Thereof |
Nov, 2030
(8 years from now) | |
| CN102712584A | ALLERGAN INC | 7-[3,5-Dihydroxy-2- (3-Hydoroxy-5-Phenyl-Pent-1-Enyl)- Cyclopentyl]-N-Ethyl-Hept-5-Enamide (Bimatoprost) In Crystalline Form Ii, Methdo For Preparation, And Method For Use Thereof |
Nov, 2030
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398707 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(1 year, 7 months from now) | |
| US8673341 | ALLERGAN INC | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb, 2025
(2 years from now) | |
| US9149428 | ALLERGAN INC | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(4 years from now) | |
| US10441543 | ALLERGAN INC | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(4 years from now) | |
| US8206737 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(4 years from now) | |
| US7799336 | ALLERGAN INC | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2029
(6 years from now) | |
| US9492316 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(12 years from now) | |
| US9980974 | ALLERGAN INC | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(12 years from now) | |
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 10MCG | IMPLANT;OPHTHALMIC | Prescription |
2. Drug name - LATISSE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8038988 | ALLERGAN | Method of enhancing hair growth |
Aug, 2023
(10 months from now) | |
| EP2802331B1 | ALLERGAN | Topical Treatment For Chemotherapy Induced Eyelash Loss Or Hypotrichosis Using Prostamide F2 Alpha Agonists |
Jan, 2033
(10 years from now) | |
| EP2802331A1 | ALLERGAN | Topical Treatment For Chemotherapy Induced Eyelash Loss Or Hypotrichosis Using Prostamide F2 Alpha Agonists |
Jan, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8986715 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(3 months from now) | |
| US9226931 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(3 months from now) | |
| US8758733 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(3 months from now) | |
| US9216183 | ALLERGAN | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
Jan, 2023
(3 months from now) | |
| US8632760 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(3 months from now) | |
| US8263054 | ALLERGAN | Method of enhancing hair growth |
Jan, 2023
(3 months from now) | |
| US8101161 | ALLERGAN | Method of enhancing hair growth |
May, 2024
(1 year, 7 months from now) | |
Treatment: Method of increasing hair growth; Method of increasing growth of hair including eyelashes; Method of increasing eyelash growth; Method of increasing eyelash growth including length, thickness, darkness and/or number of eyelashes by administering bimatoprost to an eyelid margin; Method of stimulating hair growth; method of increasing hair growth
Dosage: SOLUTION/DROPS;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.03% | SOLUTION/DROPS;TOPICAL | Prescription |
3. Drug name - LUMIGAN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7851504 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(4 years from now) | |
| CN101137383B | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| CN102240292A | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| CN101137383A | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| CN102240292B | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| IN200706652P1 | ALLERGAN | Enhanced Bimatoprost Opthalmic Solution |
Mar, 2026
(3 years from now) | |
| IN263623B | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| EP1753434B1 | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| EP1753434A2 | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| EP1753434B2 | ALLERGAN | Enhanced Bimatoprost Ophthalmic Solution |
Mar, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8278353 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8772338 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8309605 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8586630 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8524777 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US9155716 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8338479 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8299118 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US9241918 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8933120 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
| US8933127 | ALLERGAN | Enhanced bimatoprost ophthalmic solution |
Mar, 2025
(2 years from now) | |
Treatment: A method of lowering intraocular pressure; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; method of treating glaucoma in a patient; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.01% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.